Market Research Logo

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025

EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025

Summary

Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.

In the 8MM, GlobalData epidemiologists forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. GlobalData epidemiologists estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.

Scope

  • The Meningococcal disease (IMD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1-4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation.
  • The IMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
Reasons to buy

The IMD EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global IMD market.
  • Quantify patient populations in the global IMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for IMD therapeutics in each of the markets covered.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and morbidities
2.3 Global Trends
2.3.1 US
2.3.2 5EU
2.3.3 Japan and Brazil
2.4 Forecast Methodology
2.4.1 Sources Used Tables
2.4.2 Forecast Assumptions and Methods
2.4.3 Sources Not Used
2.5 Epidemiological Forecast for IMD (2015-2025)
2.5.1 All IMD Combined
2.5.2 Laboratory-Confirmed Incident Cases of Serogroup B IMD
2.5.3 Laboratory-Confirmed Incident Cases of Serogroup C IMD
2.5.4 Laboratory-Confirmed Incident Cases of Serogroup Y IMD
2.5.5 Laboratory-Confirmed Incident Cases of Other Serogroup IMD
2.5.6 Distribution of Serogroups
2.5.7 US College Freshmen
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 Limitations of the Analysis
2.6.3 Strengths of the Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologists
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head of Healthcare
3.3 About GlobalData
3.4 About EpiCast
3.5 Disclaimer
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for IMD
Table 2: 8MM, Sources of Laboratory-Confirmed IMD Incidence
Table 3: 8MM, Sources of Laboratory-Confirmed Serogroup B IMD Incidence
Table 4: 8MM, Sources of Laboratory-Confirmed Serogroup C IMD Incidence
Table 5: 8MM, Sources of Laboratory-Confirmed Serogroup Y IMD Incidence
Table 6: 8MM, Sources of Laboratory-Confirmed Other Serogroup IMD Incidence (Includes Serogroups A, W-135, X, and All Others)
Table 7: 5EU, Japan, and Brazil Sources of Laboratory-Confirmed Serogroup W-135 IMD Incidence
Table 8: Germany, Italy, and Brazil, Sources of Laboratory-Confirmed Serogroup A IMD Incidence
Table 9: College Freshmen Residing in Campus Accommodation
Table 10: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 11: 8MM and Japan, Age-specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
Table 12: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, N (Row %), 2015
Table 13: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N (Row %), 2015
Table 14: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Table 15: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 16: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 17: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Table 18: College Freshmen in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025
1.2 List of Figures
Figure 1: Laboratory-Confirmed Incidence of IMD in the EU, All Ages, Both Sexes, 2000-2014
Figure 2: 8MM, Laboratory-Confirmed Incident Cases of all IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 3: 7MM, Age-Specific Laboratory-Confirmed Incident Cases of IMD, Both Sexes, 2015
Figure 4: 8MM, Laboratory-Confirmed Incident Cases of All IMD, All Ages, Both Sexes, N, 2015
Figure 5: 8MM, Age-Standardized Laboratory-Confirmed Incidence (Cases per 100,000 Population) of IMD, All Ages, by Sex, 2015
Figure 6: 8MM, Laboratory-Confirmed Incident Cases of Serogroup B IMD, All Ages, Both Sexes, N, Selected Years 2015-2025
Figure 7: 8MM, Laboratory-Confirmed Incident Cases of Serogroup C IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 8: 8MM, Laboratory-Confirmed Incident Cases of Serogroup Y IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 9: 8MM, Laboratory-Confirmed Incident Cases of Other Serogroup IMD, All Ages, Both Sexes, N, Selected Years, 2015-2025
Figure 10: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2015
Figure 11: 8MM, Serogroup Distribution of Laboratory-Confirmed Incident IMD Cases, %, 2025
Figure 12: College Freshmen Living in Campus Accommodation in the US, All Ages, Both Sexes, N, Selected Years, 2015-2025

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report